MYL:NSD-Mylan N.V (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | NSD

Last Closing Price

USD 0.08

Change

0.00 (0.00)%

Market Cap

USD 8.59B

Volume

1.99M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

MYL Stock Forecast & Price:
Based on the Mylan N.V stock forecasts from 0 analysts, the average analyst target price for Mylan N.V is not available over the next 12 months. Mylan N.V’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Mylan N.V is Very Bullish, which is based on 2 positive signals and 0 negative signals. At the last closing, Mylan N.V’s stock price was USD 0.08. Mylan N.V’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +0.00% over the last year.

No recent analyst target price found for Mylan N.V
No recent average analyst rating found for Mylan N.V

About Mylan N.V (MYL:NSD)

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredien ...Read More

Company Website : http://www.mylan.com

Address : Building 4, Hatfield, United Kingdom, AL10 9UL

Employees : 35,000

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.47

Short Ratio : 11.15

Shorted Shares : 47,144,965

200 Day Moving Average : 16.12

Shorted Shares Previous Month : 46,489,413

50 Day Moving Average : 16.42

Shares Held By Insiders : 0.91%

Short Percentage : 11.05%

Shares Held by Institutions : 90.50%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-16 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NBIX Neurocrine Biosciences Inc

-1.28 (-1.19%)

 USD10.27B 826.08 212.29
APHA Tilray, Inc

N/A

 USD6.86B 60.60 454.68
MNTA Momenta Pharmaceuticals, Inc

N/A

 USD6.24B N/A N/A
LNTH Lantheus Holdings Inc

-0.32 (-0.38%)

 USD5.75B 199.29 50.44
ITCI Intracellular Th

+1.28 (+2.44%)

 USD4.96B N/A -15.27
PCRX Pacira Pharmaceuticals Inc

+0.22 (+0.38%)

 USD2.65B 68.73 22.46
HCM HUTCHMED DRC

-0.24 (-1.73%)

 USD2.40B 17.69 -5.96
TLRY Tilray Inc

-0.09 (-2.10%)

 USD2.34B 9.83 -10.33
ALVO Alvotech Ordinary Shares

+0.11 (+1.20%)

 USD2.27B N/A -134.36
DVAX Dynavax Technologies Corporati..

-1.38 (-8.83%)

 USD1.98B 9.89 7.28

ETFs Containing MYL

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain -99.74% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.74% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -40.56% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -40.56% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 38.26% N/A N/A N/A N/A
Risk Adjusted Return -106.02% N/A N/A N/A N/A
Market Capitalization 8.59B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 30.73 N/A N/A N/A N/A
Price/Book Ratio 1.64 N/A N/A N/A N/A
Price / Cash Flow Ratio 4.76 N/A N/A N/A N/A
EV/EBITDA 11.86 N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 1.73% N/A N/A N/A N/A
Return on Assets 3.63% N/A N/A N/A N/A
Debt to Equity Ratio 94.37% N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 11.15 N/A N/A N/A N/A
Short Percent 11.05% N/A N/A N/A N/A
Beta 1.47 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date
New Post

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:

There is nothing we particularly dislike